RxDoctor Payments DataLook up a doctor →

Ausberto Hidalgo

General Practice · Pembroke Pines, FLNPI 1144385592

Payments from drug & device makers

$2,920,283in general payments, 2019–2025

Across 282 payments — averaging $10,356 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1.7M
  • Gilead$799K
  • Cipla USA Inc.$193K
  • Sanofi US Services Inc.$135K
  • Novavax Inc$35K
  • AbbVie$19K
  • plus $15K from 8 others
$1,389in research payments, 2019–2025

Across 5 payments — averaging $277.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$850
  • Novavax Inc$540

What the payments were for

  • Speaking & faculty fees$170,744100%
  • Food & beverage$5430%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,920,283 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$44,599
Medicare patients
66
Services billed
479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$36,758
JardianceEmpagliflozin11$10,132
Testosterone Cypionate15$967
Methylprednisolone83$578
Albuterol Sulfate HfaAlbuterol Sulfate33$486
Azithromycin105$335
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav27$261
Alprazolam28$174
Acetaminophen-CodeineAcetaminophen With Codeine19$148
Ondansetron Hcl15$124
Mupirocin16$79
Naproxen11$67
Cyclobenzaprine Hcl17$67
Ciprofloxacin Hcl12$65
Levofloxacin12$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$252$36,75835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →